Ameriprise’s Ovid Therapeutics OVID Stock Holding History

Ameriprise’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-78,034	Closed	-$443K	–	3740
2018 Q3	$443K	Sell	78,034 -116,328	-60%	-$882K	﹤0.01%	3331
2018 Q2	$1.51M	Sell	194,362 -13,190	-6%	-$113K	﹤0.01%	2846
2018 Q1	$1.47M	Sell	207,552 -7,795	-4%	-$63.1K	﹤0.01%	2808
2017 Q4	$2.13M	Sell	215,347 -84,430	-28%	-$775K	﹤0.01%	2627
2017 Q3	$2.57M	Sell	299,777 -58,691	-16%	-$489K	﹤0.01%	2475
2017 Q2	$3.76M	Buy	+358,468	New	+$4.68M	﹤0.01%	2283

Other funds holding OVID

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ameriprise's OVID Position: Q4 2018 in Review

Ameriprise sold out of Ovid Therapeutics (OVID) in Q4 2018, closing a stake of 78,034 shares — an estimated $443K sold.

Ameriprise first reported a position in OVID in Q2 2017 and held it in 6 quarters. The position peaked at $3.76M in Q2 2017. 47 funds tracked by Wall St. Rank hold OVID as of Q4 2018.

Ameriprise reported no remaining Ovid Therapeutics position as of Q4 2018 after selling out during the quarter.
Ameriprise sold 78,034 Ovid Therapeutics shares in Q4 2018, an estimated $443K.
Ameriprise first reported a position in Ovid Therapeutics in Q2 2017 and held it in 6 quarters.
Ameriprise's Ovid Therapeutics position peaked at $3.76M in Q2 2017.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2018.

Based on Ameriprise's 13F filing for Q4 2018, filed 14 Feb 2019.